Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
News provided by
Share this article
Share this article
PALO ALTO, Calif., March 1, 2021 /PRNewswire/ Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter ended December 31, 2020. Our Phase 1b data show two in every three patients are on a 6-month or longer treatment free interval at Year 1 in each of the three major retinal vascular diseases after only three loading doses , said Victor Perlroth, MD, Chief Executive Officer of Kodiak. Importantly, the durability profile of KSI-301 is tied to strong efficacy improvements in all three diseases at Year 1. The treatment naïve wet AMD patients in our study achieved 20/40 vision on average at Year 1 and DME